Kindred Biosciences, Inc. (KIN) saw its loss narrow to $5.68 million, or $0.29 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $7.10 million, or $0.36 a share.

The company has not recorded any revenues for the current as well as previous quarter.

Operating loss for the quarter was $5.78 million, compared with an operating loss of $7.13 million in the previous year period.

"We are pleased with the progress across our programs as we execute our strategy of quickly and cost-effectively developing therapeutics for our animal family members. In support of the anticipated launch of ZimetaTM (dipyrone injection) and MiratazTM (mirtazapine 2% ointment), we have been hiring key personnel, building our veterinary technical services and establishing distribution channels. The advances of our lead candidates are complemented by promising preliminary data from pilot studies on our industry-leading biologics pipeline. As we prepare to transition to a revenue generating company next year, our deep product pipeline of more than 20 programs is supported by our strong cash position," stated Richard Chin, M.D., president and chief executive officer of KindredBio.